Bioactive Milk Peptides and Blood Pressure

NCT01031485•Valio Ltd

Summary

The purpose of this study is to investigate the effects of bioactive milk peptides on blood pressure in mildly hypertensive subjects.

Eligibility

Age

30 - 60 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•age 30-60 years
•systolic blood pressure 140-160 mmHg and diastolic blood pressure 90-99 mmHg in office measurement
•apparently healthy

Exclusion Criteria

•antihypertensive and lipid-lowering drugs
•unstable coronary artery disease, diabetes, malignant diseases, secondary hypertension
•BMI \> 32 kg/m2
•milk allergy
•smoking
•alcohol abuse
•pregnancy, lactation
•simultaneous participation in other clinical trial

Locations (1)

Valio Ltd

Helsinki, Uusimaa, Finland

Key Dates

Start Date

January 1, 2010

Primary Completion Date

June 1, 2010

Completion Date

August 1, 2010

Last Updated

December 23, 2014

Conditions

Stage 1 Hypertension

Interventions

Milk peptides and plant sterols

DIETARY_SUPPLEMENT

Placebo

OTHER

Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

NCT01508026

Stage 1 HypertensionStage 2 Hypertension

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 23, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions